Sichenzia Ross Ference represented Relmada Therapeutics in the transaction. Relmada Therapeutics, Inc. (NASDAQ: “RLMD”), a late-stage biotechnology company, executed a $100 million At-The-Market offering facility (“ATM”)....
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
